CIPROFLOXACIN IN DEXTROSE 5% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ciprofloxacin In Dextrose 5%, and what generic alternatives are available?
Ciprofloxacin In Dextrose 5% is a drug marketed by Hikma Farmaceutica, Baxter Hlthcare, Baxter Hlthcare Corp, Bedford, Hospira, Inforlife, and Teva Pharms. and is included in eight NDAs.
The generic ingredient in CIPROFLOXACIN IN DEXTROSE 5% is ciprofloxacin. There are thirty-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ciprofloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ciprofloxacin In Dextrose 5%
A generic version of CIPROFLOXACIN IN DEXTROSE 5% was approved as ciprofloxacin by BAXTER HLTHCARE CORP on April 29th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CIPROFLOXACIN IN DEXTROSE 5%?
- What are the global sales for CIPROFLOXACIN IN DEXTROSE 5%?
- What is Average Wholesale Price for CIPROFLOXACIN IN DEXTROSE 5%?
Summary for CIPROFLOXACIN IN DEXTROSE 5%
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 3 |
Clinical Trials: | 301 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CIPROFLOXACIN IN DEXTROSE 5% at DailyMed |
Recent Clinical Trials for CIPROFLOXACIN IN DEXTROSE 5%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Prostate Cancer Foundation | Phase 1/Phase 2 |
Institute of Cancer Research, United Kingdom | Phase 1/Phase 2 |
Shanghai Pulmonary Hospital, Shanghai, China | Phase 4 |